Journal article
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, AK Nooka, H Quach, C Lee, W Barreto, P Corradini, CK Min, EC Scott Show all
Haematologica | Published : 2018
Open access
Abstract
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; ha zard ra ti o, 0.3 1; 95% confidence interval, 0.24 -0.39; P<0.0001) and improved the overall response rate (83.8% versus 63.2%; P<0.0001) compared with bortezomib an..
View full abstractGrants
Funding Acknowledgements
This study was sponsored by Janssen Research & Development, LLC. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency.As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.